Although largely as expected by investors, BMO Capital says lenacapavir’s approval for prevention, now known as Yeztugo, marks “a major win for Gilead (GILD)” in driving meaningful growth in its pre-exposure prophylaxis business. A clean label, strong clinical data, and a convenient twice yearly dosing regimen, in line with patient physician visits, should drive strong commercial adoption for Yeztugo, says the analyst, who has an Outperform rating and $120 price target on Gilead shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Cautious Optimism for Gilead Sciences Amid Yeztugo’s Market Challenges
- Morgan Stanley says FDA approval of Yeztugo ‘an expected positive’ for Gilead
- Mizuho says Gilead Yeztugo label looks clean
- Gilead Sciences’ Yeztugo Approval and Market Expansion Drive Buy Rating
- Gilead announces FDA approves Yeztugo as twice-a-year HIV prevention option